PCa is a highly heterogeneous disease, and so far, most of the treatment-decision algorithms depend on risk stratification based on the tumour stage, the prostate-specific antigen (PSA) level at the time of diagnosis, and the Gleason grade group (GG) (2). Here, PROS1 is linked to posterior cortical atrophy.